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ABSTRACT

OBJECTIVE: The objective of this selective EBM review is to determine whether or not
vitamin D supplement is effective in improving physical performance in older patients with heart
failure over the age 50 years
STUDY DESIGN: Review of three English language primary studies, two published in 2010
and one was published in 2013.
DATA SOURCES: Two double blind randomized controlled trials (RCT) and one crosssectional study that investigated the use of vitamin D in improving physical performance in heart
failure. Sources were selected and found using PubMed, ScienceDirect, and Cochrane databases.
OUTCOMES MEASURED: The outcomes measured were improvement of physical
performance, and associations among muscle strength, health status measures, and serum vitamin
D. Tools used to measure were, a 6 minute walk distance test (6MWD), timed get up and go test
(TGUG), isokinetic muscle testing.
RESULTS: The results of two RCT studies Boxer et al. (2013) and Witham et al. (2013)
supported that vitamin D does not improve physical performance. The Boxer et al. (2010) crosssectional study showed no association among serum vitamin D concentration, muscle strength,
and health status. Boxer et al. (2013) and Witham et al. (2013) demonstrated that the 6MWD test
and TGUG test did not improve with physical activity.
CONCLUSION: The results of the RCT’s and the cross-sectional study reviewed; suggest that
Vitamin D does not improve the physical performance of older adults with heart failure. This
topic does warrant additional research. Further studies conducted should include more frequent,
lower doses of vitamin D and examine the results for a longer period of time. The effects of sunexposure on vitamin D concentration and improvement of physical activity also should be
investigated.
KEY WORDS: Vitamin D, Heart Failure, Physical Performance.
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INTRODUCTION
Heart failure is identified as an abnormality in heart structure or function leading to
inability of the heart to pump blood at an output sufficient to meet requirements of metabolizing
tissues or the ability to do so at abnormally elevated diastolic pressures/volume.1 Average age of
patients with heart failure is 76 years in the United Kingdom, with 10% of populations aged ≥ 80
years have heart failure.2 The incidence of heart failure increases fourfold between the ages of
65 and 85 years .3 Heart failure is currently the most common cause of hospitalization in the
persons in the Medicare age group; more than 70% of the nearly 1 million annual
hospitalizations for heart failure involve persons older than 65 years of age. 3 Between 1 and 2%
of the total health care budget in many developed countries is spent on hospitalizations resulting
from heart failure. In 2009, the total cost of heart failure was estimated to be $37.2 billion in the
United States.4
Decline in physical function and poor quality of life remains main characteristics of the
patients with heart failure. Currently management of patients with heart failure is limited to
pharmacology therapy and diet plans to prevent the progression of the disease.1 Patients with
NYHA Class I-III heart failure have benefitted from regular, mild exercises, such as walking or
using stationary-bicycles.1 Despite the therapies available to patients with heart failure, physical
functioning remains poor in older adults with heart failure. Several studies; including Boxer et
al. (2008) have demonstrated that vitamin D deficiency is associated with reduced physical
performance and frailty.5 Repletion of vitamin D has shown to result in improvement in strength
and balance and reduced risk of falls.6 Evidence shows that vitamin D also down-regulates the
renin-angiotensin system (RAAS)7 and reduces blood pressure,7 which both can be of particular
importance in patients with heart failure according to the hypothesis that dysregulation of
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neurohormanal pathways leads to muscle myopathy.6 Heart failure and vitamin D deficiency are
both common in older adults.8 Therefore, vitamin D supplementation could improve the physical
performance in older individuals with heart failure.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “vitamin D
supplementation is effective in improving physical performance in older patients with heart
failure who are over the age of 50 years.”
METHODS
The selected articles included men and women with heart failure who were older than 50
years of age. The intervention chosen in the two RCT’s was oral vitamin D compared to a
placebo. The cross-sectional study examined the association among serum vitamin D, muscle
strength and health status. The outcomes addressed included improvement of physical
performance, on 6 minute walk distance test (6MWD) and timed get up and go (TGUG).
Associations among serum vitamin D concentration, muscle strength, and health status were
studied in cross sectional study by measuring vitamin D levels and muscle strength. The types of
studies included were two RCTs, and one cross-sectional study.
Key words vitamin D, heart failure and physical performance were searched using the
following search engines: PubMed, ScienceDirect, and Cochrane Database. Articles selected
were written in the English language, peer reviewed, and published between 2010 and 2013 and
had not been previously used in a systematic review or meta-analysis. Inclusion criteria for these
studies were RCTs that were published in 2000 or later based on their relevance and importance
of the outcome to the patient (Patient Oriented Evidence That Matters, POEMS) and that
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investigated the effectiveness of vitamin D in improving physical performance in patients with
heart failure (Table 1). Exclusion criteria consisted of studies that investigated patients younger
than age 50 years, without a diagnosis of heart failure, patients who were taking daily vitamin D
supplements, and patients with a diagnosis of osteoporosis (Table 1). Statistics were reported
using mean±SD change from baseline, linear regression model, ANCOVA, Pearson X2, Pearson
product moment correlation, and p-value
OUTCOMES MEASURED
The outcomes were measured via several different methods. Boxer et al. (2013) measured
physical performance at base line and 6 months with the TGUG and 6MWD. TGUG is a reliable
and valid test of basic mobility maneuvers, including balance, gait, speed, strength, and
functional ability used in measuring clinically significant changes in mobility in older frail
patients.2 6MWD has been validated for patients with heart failure; it reflects the type of aerobic
activity that older persons with health failure undertake.2 Both of these tests are globally used in
older individuals to measure basic mobility. They closely mirror the type of aerobic activity that
older persons with health failure undertake. Witham et al. (2013) measured physical performance
using TGUG and 6MWD. To measure muscle strength, Boxer et al. (2010) used Biodex System
3 Pro Isokinetic Dynamometer. Health status was assessed the by Kansas City Cardiomyopathy
Questioner, a 23-item self-administered instrument. Serum analysis was performed by collecting
blood, and measuring vitamin D levels by Chemiluminescent Immunoassay.
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Table 1 - Demographics & Characteristics of Included Studies
Study
Type
#
Age
Inclusion
Exclusion
Pts
criteria
criteria
Cross
Boxer
40 67.8
Patients’ age
primary
sectional
(2010)
±10.9 ≥50 with
hyperparathyroi
years either systolic dism or
or preserved
hypercalcemia;
systolic
nephrolithiasis;
function HF.
diagnosis of
25OHD
osteoporosis;
concentration hemodialysis or
b37.5 ng/mL
peritoneal
dialysis and/or
creatinine of
N2.5 mg/dL;
current use of
daily vitamin D
N400 IU,
corticosteroids,
PTH, androgen,
estrogen
Boxer
Double 64 65.9
Patients age ≥ Primary
(2013)
Blind
±10.4 50, with HF in hyperparathyroi
RCT
years class II to IV. dism, sarcoid,
Receiving
hypercalcemia,
maximum
nephrolithiasis,
doses of
osteoporosis,
evidencecreatinine >2.5
based HF
mg/dl,
medication.
vitamin D
The required
supplementatio
serum 25
n >400 IU/day
(OH)D level
≤37.5ng/ml.
Witham Double 105 aged aged ≥ 70
clinical
(2010)
Blind
≥70
years with
diagnosis of
RCT
years diagnosed
osteomalacia,
chronic heart
under
failure and
investigation for
25recurrent falls,
hydroxyvitam already taking
in D level of < vitamin D
50 nmol/L
supplements,
moderate to
severe cognitive
impairment

W/D

intervention

0

Association
among
Serum
25OHD
(vitamin D)
and muscle
strength

10 –
W/D

vitamin D3
50,000 IU
daily for 6
months

2Diseased

64included
in
analysis

6 due to
death
1 ill
health
2 other
reasons
105included
in
analysis

100,000 U
of oral
vitamin D2
at baseline,
10 weeks,
and 20
weeks
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RESULTS
The three articles presented in this review had continuous data, which could not be
converted to dichotomous data. In the study done by Boxter et al. (2013), the reported statistics
compared oral vitamin D supplement to placebo. The results of the TGUG and 6MWD, were
calculated for vitamin D (n=31) group, and placebo group (n=33) as mean ±SD, at baseline and 6
months (Table 2). The treatment effect, (vitamin D versus placebo) was evaluated at each end
point by ANCOVA model as frequencies and proportions for categorical variables within study
groups. In TGUG and 6MWD, the differences in physical function improvement between the
vitamin D group and placebo group were 0.8 and 20, respectively.6 The results did not reach a
statistically significant value, p=0.306 (TGUG) and p=0.806 (6MWD) (Table 2).
Table 2 - Change in Aerobic Capacity and Muscle Strength in the vitamin D and Placebo Groups
6-Month change in endpoint
ANCOVA model
End point
Vitamin D (=31)
Placebo (n=33)
TGUG
-.02 ± 3.3
-1.0 ± 3.3
baseline to 6 mo
6MWD (m)
59 ± 282
36 ± 228
Baseline to 6 mo
Values are mean ± SD. ANCOVA= analysis of covariance

Vitamin D – Placebo
Difference
0.8
20

p value
0.30
0.80

In the study performed by Witham et al. (2013) statistics reported; compared vitamin D
supplement to placebo. Differences between groups were compared at baseline versus 10 weeks,
and base line versus 20 weeks. Pearson X2 test was used to compare categorical variables. Of the
participants in the placebo group (n=52), 46 (88%) completed 6MWD test at the end of week
10th, compared with 45 (85%) in the treatment group (n=53). In the 6MWT, a change of 30 m in
distance is the minimum required to show clinical improvements.2 The between group difference
at baseline versus 10 weeks showed no significant improvement. -2.4 (95% confidence interval
[CI], -17.1 to 12.4); (p=0.75). 2 (Table 3). At 20 weeks, 42 participants in each group (81% in

Yazdani, Vitamin D for HF 6

placebo and 79% in vitamin D group) were able to complete the 6MWD. Unadjusted analysis
(Table 3) and adjusted analysis (for key variables at baseline) showed no improvement with
vitamin D supplementation p=0.512 in unadjusted analysis (Table3) and p=0.682 in adjusted
analysis. Also outcomes on TGUG showed no improvement with vitamin D supplementation2
(Table 3). The score of TGUG at 10 weeks and 20 weeks showed no significant improvement in
function either. At week 10, the between group difference was 0.21 (CI -1.79 to 1.37); (p= 0.80),
and at 20 weeks, the between group difference was 1.42 (CI -1.13 to 3.97); (p=.27); (Table 3). 2
Table 3- Changes in Outcome Measures
0 VS. 10 weeks

6-min, m
TGUG, s

Between- group
Difference (95% CI)
-2.4(-17.1 to 12.4)
0.21(-1.79 to 1.37)

0 VS. 20 weeks
p

0.75
0.80

Between- group
Different (95% CI)
-5.6(-22.2 to 11.0)
1.42(-1.13 to 3.97)

p
0.51

0.27

In the last study, Boxer et al. (2010) assessed the association among serum vitamin D
concentrations (a level of ≤0.05 was considered significant), physical performance, and health
status. A linear regression model then studied the association after adjusting for other potential
variables.7 The mean serum vitamin D concentration was 18.5 ± 9.1 ng/m.7 The levels varied by
race, with African Americans having the lowest (16 versus 22 ng/ml, p=0.4). Muscle strength
was measured by weight bearing ability in flexion, with men having a mean (n=18) of 17.1 ± 6.7,
and women (n=21) of 16.1 ± 6.1. 7 There was no association between serum vitamin D
concentration and muscle streghth.7 Data showed, “Older age trended toward significance at
p=0.08, with older age relating to lower peak torque.” 7 The mean total score on Kansas City
Cardiomyopathy Questionnaire (KCCQ) was 68.9 ± 22.9.7 There was also no association
between KCCQ total score and serum vitamin D concentrations. However, there was an
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association between serum vitamin D levels and physical limitation scores, which is one of the
four domains of KCCQ (r=0.32, and p= 0.04)7. However, after data were adjusted for African
Americans (with lowest score) and New York Heart Association (NYHA), (lower class of heart
failure had highest score), the association was lost.7
In the two RCT’s, control groups were vitamin D groups. However, in the cross-sectional
study there was no control group, and association between three variables was studied. Each
study had specific inclusion/exclusion criteria. They all included patients in NYHA functional
Class II to IV who were 50 years of age or older. Boxer et al. (2010) and Boxer et al. (2013)
excluded patients who were taking daily vitamin D supplements of > 400 IU and with a
diagnosis of osteoporosis. Witham et al. (2013) excluded any patient who was taking any daily
dose of vitamin D and those with a current diagnosis of osteopenia.
In Boxer et al. (2013) study, six patients from the control group and six patients from the
placebo group did not complete the trial.6 One patient in each group died and five in each group
withdrew.6 The monthly pill counts showed 100% compliance in the vitamin D group and 99.5%
in the placebo group.6 Witham et al. (2013) reported, the death of two patients in each group
before completion of Week 10, and another two deaths in control group before Week 20. One
individual dropped of the control group because of ill health before Week 20. One patient in the
placebo group violated the protocols and was dropped between Week 10 and 20 and one other
patient in the placebo group moved away between Week 10 and 20 and thus dropped out.1 To
ensure adherence, a research nurse directly observed each patient take the pill in the
participant’s own home.1 Adherence was reported 100% throughout.”1
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Both the Boxer et al. (2013) and Witham et al. (2013) studies showed interventions were
well tolerated.2, 6 Boxer et al. reported no significant difference between the control group and
the placebo group with the exception of increasing numbers of infections in the vitamin D group
(18 compared to six).6 Witham et al. (2013) reported an increase of creatinine of greater than
25% in five patients in the vitamin D group compared to one patient in the placebo group
(p=0.11).2
DISCUSSION
The results from Boxer et al. (2013) and Witham et al. (2013) studies, showed physical
performance in older patients with heart failure did not improve by vitamin D supplementation.2,6
Boxer et al. (2010) found no association between the serum vitamin D concentrations and muscle
strength.7 The studies performed contained some factors that may have affected the outcome
results. Boxer et al. (2013) used a diverse study population with strong presentation of women.6
Witham et al. (2013) study included a large sample size however, it underrepresented women.7
On the other hand, Witham et al. states “30 m is the minimum clinically important
improvement”2 6MWT. Also the subsequent narrow CI around the 6MWT “makes it unlikely
that any clinically significant effect were missed in Witham study.”2 Such result is in agreement
with the findings of studies investigated in this paper.
Result from the study of vitamin D effects in older individuals without a diagnosis of
heart failure with vitamin D insufficiency, showed some benefits in physical performance after
treatment with vitamin D.8 Small and frequent dose of 800 to 1000 IU/day of vitamin D, and
specifically combined with calcium has shown benefits in the results of TGUG but not 6MWD.7
Boxer et al. (2013) study used high dose of vitamin D3 with calcium as intervention. It is
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possible that a smaller, more frequent dose of vitamin D3 might be beneficial in improvement of
physical performance in older patients with heart failure. Witham et al. (2013) did not use any
calcium with the vitamin D administration.2
Outcomes in the Boxer et al. (2013) and Witham et al. (2013) studies could be different if
therapy was continued for a longer period of time. A longer duration therapy with the vitamin D
could elicit changes in physical function.2, 6 Boxer et al. (2010) study was limited by crosssectional design due to the fact that it only studied association between variables. Sample sizes in
Boxer et al. (2013) and Boxer et al. (2010) were too small.6, 7 A larger sample size could lead to
different outcomes in both studies. Boxer et al. (2013) explains that it is theorized vitamin D
reduces the risk for infection and inflammations,6 however the most significant adverse event in
this study was the higher number of infections in vitamin D group compared to the placebo
group,6 “This might be due to small sample size or to multiple comparisons.”6 Witham et al.
(2013) study used vitamin D2 (because it was the largest dose of oral vitamin D available).
Vitamin D3 has a greater peak levels and longer half-life, therefore results in Witham et al.
(2013) could be different if vitamin D3 was used as intervention.2
Vitamin D supplements are readily available over the counter in United States. Vitamin D
is thought to be important for maintaining normal function of tissues such as muscle (including
heart muscle), immune function, and inflammation.1 The U.S. National Academy of Science
recommends 800 IU vitamin D/day from food and supplement.1 Vitamin D intoxication is rare
but it can cause hypercalcemia.1
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CONCLUSION
The results of the RTC’s studies suggested that vitamin D does not improve the physical
performance in the older adults with the heart failure. The cross-sectional study indicated there is
no association between serum vitamin D levels and muscle strength.
Future studies should be conducted with Vitamin D treatment starting at the earliest stage
of HF to determine whether increasing Vitamin D concentration to an optimal level will prevent
progression of HF and manifestation of physical functioning decline. In addition further studies
should be conducted with lower doses and more frequent doses of vitamin D with conjunction of
including a larger sample size.
Boxer et al. (2010) points out to the importance of sun-exposure in maintaining the serum
concentration level of vitamin D.7 Patients with heart failure have limited mobility ability and
therefore might be deprived from sun-exposure. Future studies are warranted to investigate the
relation of sun-exposure to serum concentration level of vitamin D and its effect on physical
performance in patients with heart failure.
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